The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine

Phase 4CompletedNCT00197782

Public Health England

Overview

To measure the magnitude and persistence of the antibody response to a booster dose of Hib conjugate vaccine given between 9 months and 4 years of age to UK children who had completed primary immunisation with 3 doses of Hib vaccine given at 2/3/4 months of age either as a combined D/T/wholecellpertussis/Hib or D/T/acellularpertussis/Hib vaccine.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Conditions

Haemophilus Influenzae Type b

Interventions

Hib conjugate vaccineBIOLOGICAL

Eligibility

Sex: ALLMin age: 9 MonthsMax age: 4 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent from parent or legal guardian of the infant or child * Age \>= 9 months and \<4 years at recruitment * Eligible to receive a single dose of Hib vaccine as per the UK schedule * Receipt of three doses of Hib vaccine in infancy Exclusion Criteria: * History of Hib infection * History of severe local reaction that can be confidently related to a prior Hib immunisation * Deferral of vaccination if acute illness and/or temperature \>38C on day of vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.